Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study.
9vHPV
Adolescents
Coadministration
Immunogenicity
Invasive meningococcal disease
MCV4-TT
MenACYW-TT
Safety
Tdap-IPV
Vaccination
Journal
Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499
Informations de publication
Date de publication:
02 Jul 2024
02 Jul 2024
Historique:
received:
15
03
2024
accepted:
13
06
2024
medline:
3
7
2024
pubmed:
3
7
2024
entrez:
2
7
2024
Statut:
aheadofprint
Résumé
Many immunization programs in Europe recommend quadrivalent meningococcal vaccinations, which are often administered concomitantly with other vaccines. We compared the immune response of a tetanus toxoid conjugated quadrivalent meningococcal vaccine (MenACYW-TT, MenQuadfi In this phase IIIb trial, healthy adolescents (MenC-naïve or MenC-primed before 2 years of age) from Spain, Italy, Hungary, and Singapore were randomized in a 3:3:2 ratio to receive either MenACYW-TT or MCV4-TT alone, or MenACYW-TT concomitantly with 9vHPV and Tdap-IPV. The primary objective was to demonstrate the non-inferiority of the seroprotection rate (human serum bactericidal assay [hSBA] titer ≥ 1:8) to serogroups A, C, W, and Y 30 days post-vaccination with a single dose of MenACYW-TT or MCV4-TT. Secondary objectives included describing hSBA titers for the four serogroups before and 1 month following vaccination and according to MenC priming status. A total of 463 participants were enrolled (MenACYW-TT, n = 173; MCV4-TT, n = 173; MenACYW-TT/9vHPV/Tdap-IPV n = 117). Non-inferiority based on seroprotection was demonstrated for MenACYW-TT versus MCV4-TT for all serogroups. Immune responses were comparable whether MenACYW-TT was administered alone or concomitantly with Tdap-IPV and 9vHPV. Post-vaccination hSBA GMTs were higher in MenACYW-TT vs. MCV4-TT for serogroups C, Y, and W and comparable for serogroup A. The percentages of participants with an hSBA vaccine seroresponse were higher in MenACYW-TT vs. MCV4-TT for all serogroups. For serogroup C, higher GMTs were observed in both MenC-naïve or -primed participants vaccinated with MenACYW-TT vs. MCV4-TT. Seroprotection and seroresponse were higher in MenC-naïve participants vaccinated with MenACYW-TT vs. MCV4-TT and comparable in MenC-primed. The safety profiles were comparable between groups and no new safety concerns were identified. These data support the concomitant administration of MenACYW-TT with 9vHPV and Tdap-IPV vaccines in adolescents. Clinicaltrials.gov, NCT04490018; EudraCT: 2020-001665-37; WHO: U1111-1249-2973. MenACYW conjugate vaccine has been made to protect against meningococcal disease caused by four common types of bacteria (germs) called Neisseria meningitidis (or meningococcus), A, C, W, and Y. Many people, particularly adolescents, have the germs of this disease in their nose or throat, and therefore may develop the disease or transmit the bacteria to other people. Hence, adolescent meningococcal vaccination against serogroups ACWY is increasingly recommended in several countries. This study assessed the immune response to these serogroups in healthy adolescents after one dose of MenACYW conjugate vaccine or Nimenrix
Autres résumés
Type: plain-language-summary
(eng)
MenACYW conjugate vaccine has been made to protect against meningococcal disease caused by four common types of bacteria (germs) called Neisseria meningitidis (or meningococcus), A, C, W, and Y. Many people, particularly adolescents, have the germs of this disease in their nose or throat, and therefore may develop the disease or transmit the bacteria to other people. Hence, adolescent meningococcal vaccination against serogroups ACWY is increasingly recommended in several countries. This study assessed the immune response to these serogroups in healthy adolescents after one dose of MenACYW conjugate vaccine or Nimenrix
Identifiants
pubmed: 38955966
doi: 10.1007/s40121-024-01009-x
pii: 10.1007/s40121-024-01009-x
doi:
Banques de données
ClinicalTrials.gov
['NCT04490018']
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases. 2023. http://atlas.ecdc.europa.eu/public/index.aspx .
Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853–61. https://doi.org/10.1016/S1473-3099(10)70251-6 .
doi: 10.1016/S1473-3099(10)70251-6
pubmed: 21075057
Knol MJ, Hahné SJM, Lucidarme J, Campbell H, de Melker HE, Gray SJ, et al. Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study. Lancet Public Health. 2017;2(10):e473–82. https://doi.org/10.1016/S2468-2667(17)30157-3 .
doi: 10.1016/S2468-2667(17)30157-3
pubmed: 29253430
Nuttens C, Findlow J, Balmer P, Swerdlow DL, Tin Tin Htar M. Evolution of invasive meningococcal disease epidemiology in Europe, 2008 to 2017. Euro Surveill. 2022. https://doi.org/10.2807/1560-7917.Es.2022.27.3.2002075 .
doi: 10.2807/1560-7917.Es.2022.27.3.2002075
pubmed: 35057902
pmcid: 8804660
Carr JP, MacLennan JM, Plested E, Bratcher HB, Harrison OB, Aley PK, et al. Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme. Clin Microbiol Infect. 2022;28(12):1649e1–8. https://doi.org/10.1016/j.cmi.2022.07.004 .
doi: 10.1016/j.cmi.2022.07.004
Maiden MC, Ibarz-Pavón AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197(5):737–43. https://doi.org/10.1086/527401 .
doi: 10.1086/527401
pubmed: 18271745
pmcid: 6767871
Kristiansen PA, Diomandé F, Ba AK, Sanou I, Ouédraogo AS, Ouédraogo R, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis. 2012;56(3):354–63. https://doi.org/10.1093/cid/cis892 .
doi: 10.1093/cid/cis892
pubmed: 23087396
European Medicines Agency. MenQuadfi. 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/menquadfi .
US Food and Drug Administration. MenQuadfi | FDA. 2023. https://www.fda.gov/vaccines-blood-biologics/menquadfi .
Chang L-J, Hedrick J, Christensen S, Pan J, Jordanov E, Dhingra MS. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine. 2020;38(19):3560–9. https://doi.org/10.1016/j.vaccine.2020.03.017 .
doi: 10.1016/j.vaccine.2020.03.017
pubmed: 32209248
Áñez G, Hedrick J, Simon MW, Christensen S, Jeanfreau R, Yau E, et al. Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study. Hum Vaccin Immunother. 2020;16(6):1292–8. https://doi.org/10.1080/21645515.2020.1733867 .
doi: 10.1080/21645515.2020.1733867
pubmed: 32209015
pmcid: 7482862
Vesikari T, Borrow R, Forsten A, Findlow H, Dhingra MS, Jordanov E. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study. Hum Vaccin Immunother. 2020;16(6):1306–12. https://doi.org/10.1080/21645515.2020.1733869 .
doi: 10.1080/21645515.2020.1733869
pubmed: 32233959
pmcid: 7538019
Knuf M, Rämet M, Breinholt Stærke N, Bertrand-Gerentes I, Thollot Y, B’Chir S, et al. Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: a randomised, controlled trial. Hum Vaccin Immunother. 2022;18(5):2052657. https://doi.org/10.1080/21645515.2022.2052657 .
doi: 10.1080/21645515.2022.2052657
pubmed: 35445641
pmcid: 9225511
Martinón-Torres F, Bertrand-Gerentes I, Oster P. A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT. Expert Rev Vaccines. 2021;20(9):1123–46. https://doi.org/10.1080/14760584.2021.1964962 .
doi: 10.1080/14760584.2021.1964962
pubmed: 34365870
Electronic Medicines Compendium. MenQuadfi solution for injection—summary of product characteristics (SmPC)-(emc). 2020. https://www.medicines.org.uk/emc/product/12818/smpc#gref .
European Medicines Agency. Nimenrix | Summary of Product Characteristics. 2024.
Macina D, Evans KE. Bordetella pertussis in school-age children, adolescents and adults: a systematic review of epidemiology and mortality in Europe. Infect Dis Ther. 2021;10(4):2071–118. https://doi.org/10.1007/s40121-021-00520-9 .
doi: 10.1007/s40121-021-00520-9
pubmed: 34435338
pmcid: 8387212
Ribeiro AA, Saddi VA, Carneiro MA, Figueiredo-Alves RR, da Silva Barros NK, de Almeida Carvalho KP, et al. Human papillomavirus and Chlamydia trachomatis infections in adolescents and young women: prevalence and risk factors. Diagn Cytopathol. 2020;48(8):736–44. https://doi.org/10.1002/dc.24460 .
doi: 10.1002/dc.24460
pubmed: 32379403
Weinberger B. Adult vaccination against tetanus and diphtheria: the European perspective. Clin Exp Immunol. 2017;187(1):93–9. https://doi.org/10.1111/cei.12822 .
doi: 10.1111/cei.12822
pubmed: 27279025
European Centre for Disease Prevention and Control. Vaccine Scheduler | ECDC. 2023. https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=3&SelectedCountryIdByDisease=-1 .
Colzani E, Johansen K, Johnson H, Pastore Celentano L. Human papillomavirus vaccination in the European Union/European Economic Area and globally: a moral dilemma. Euro Surveill. 2021. https://doi.org/10.2807/1560-7917.Es.2021.26.50.2001659 .
doi: 10.2807/1560-7917.Es.2021.26.50.2001659
pubmed: 34915976
pmcid: 8728487
European Centre for Disease Prevention and Control. Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction. 2020. https://www.ecdc.europa.eu/en/publications-data/guidance-hpv-vaccination-eu-focus-boys-people-living-hiv-9vHPV-vaccine .
Centers for Disease C, Prevention. HPV Vaccination: What Everyone Should Know | CDC. 2021. https://www.cdc.gov/vaccines/vpd/hpv/public/index.html .
Díez-Domingo J, Simkó R, Icardi G, Chong CP, Zocchetti C, Syrkina O, et al. 1139. Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Compared to a Meningococcal Reference Vaccine (MCV4-TT) in Healthy Adolescents. Open Forum Infect Dis. 2023. https://doi.org/10.1093/ofid/ofad500.980 .
doi: 10.1093/ofid/ofad500.980
pubmed: 37383245
pmcid: 10679203
Neveu D, Mallett Moore T, Zambrano B, Chen A, Kürzinger M-L, Marcelon L, et al. Structured benefit-risk assessment of a new quadrivalent meningococcal conjugate vaccine (MenACYW-TT) in individuals ages 12 months and older. Infect Dis Ther. 2023;12(10):2367–86. https://doi.org/10.1007/s40121-023-00864-4 .
doi: 10.1007/s40121-023-00864-4
pubmed: 37755671
pmcid: 10600069
Zambrano B, Peterson J, Deseda C, Julien K, Spiegel CA, Seyler C, et al. Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study. Pediatr Res. 2023;94(3):1035–43. https://doi.org/10.1038/s41390-023-02478-5 .
doi: 10.1038/s41390-023-02478-5
pubmed: 36899125
pmcid: 10000353
Burman C, Knuf M, Sáfadi MAP, Findlow J. Antibody persistence and revaccination recommendations of MenACWY-TT: a review of clinical studies assessing antibody persistence up to 10 years after vaccination. Expert Rev Vaccines. 2024. https://doi.org/10.1080/14760584.2024.2348609 .
doi: 10.1080/14760584.2024.2348609
pubmed: 38697798
Medical Dictionary for Regulatory Activities. MedDRA. 2024. https://www.meddra.org/ .
Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 1990;9(12):1447–54. https://doi.org/10.1002/sim.4780091208 .
doi: 10.1002/sim.4780091208
pubmed: 2281232
Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8):857–72. https://doi.org/10.1002/(sici)1097-0258(19980430)17:8%3c857::aid-sim777%3e3.0.co;2-e .
doi: 10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e
pubmed: 9595616
Findlow J, Balmer P, Borrow R. A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines. Hum Vaccin Immunother. 2019;15(10):2491–500. https://doi.org/10.1080/21645515.2019.1593082 .
doi: 10.1080/21645515.2019.1593082
pubmed: 30883271
pmcid: 6816443
Matsuoka O, Ujiie M, Kikuchi H, Otake S, Chansinghakul D, Inoue T, et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in meningococcal vaccine-naïve participants across a broad age range (2–55 Years) in Japan: a phase III randomized study. Jpn J Infect Dis. 2023;76(3):174–82. https://doi.org/10.7883/yoken.JJID.2022.272 .
doi: 10.7883/yoken.JJID.2022.272
pubmed: 36724939
Conti A, Broglia G, Sacchi C, Risi F, Barone-Adesi F, Panella M. Efficacy and safety of quadrivalent conjugate meningococcal vaccines: a systematic review and meta-analysis. Vaccines. 2023;11(1):178.
doi: 10.3390/vaccines11010178
pubmed: 36680022
pmcid: 9866575
Shimabukuro TT, Su JR, Marquez PL, Mba-Jonas A, Arana JE, Cano MV. Safety of the 9-valent human papillomavirus vaccine. Pediatrics. 2019. https://doi.org/10.1542/peds.2019-1791 .
doi: 10.1542/peds.2019-1791
pubmed: 31740500
Laurichesse H, Zimmermann U, Galtier F, Launay O, Duval X, Richard P, et al. Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX®) and a tetanus monovalent vaccine in healthy adults: new considerations for the management of patients with tetanus-prone injuries. Hum Vaccin Immunother. 2012;8(12):1875–81. https://doi.org/10.4161/hv.22083 .
doi: 10.4161/hv.22083
pubmed: 23032160
pmcid: 3656080
Dhingra MS, Peterson J, Hedrick J, Pan J, Neveu D, Jordanov E. Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: a phase III randomized study. Vaccine. 2020;38(33):5194–201. https://doi.org/10.1016/j.vaccine.2020.06.013 .
doi: 10.1016/j.vaccine.2020.06.013
pubmed: 32565344
Filice GA, Hayes PS, Counts GW, Griffiss JM, Fraser DW. Risk of group A meningococcal disease: bacterial interference and cross-reactive bacteria among mucosal flora. J Clin Microbiol. 1985;22(2):152–6. https://doi.org/10.1128/jcm.22.2.152-156.1985 .
doi: 10.1128/jcm.22.2.152-156.1985
pubmed: 3928679
pmcid: 268349
Tzeng Y-L, Stephens DS. Epidemiology and pathogenesis of Neisseria meningitidis. Microbes Infect. 2000;2(6):687–700. https://doi.org/10.1016/S1286-4579(00)00356-7 .
doi: 10.1016/S1286-4579(00)00356-7
pubmed: 10884620
World Health O. Defeating meningitis by 2030: baseline situation analysis. 2010. https://cdn.who.int/media/docs/default-source/documents/health-topics/meningitis/bsa_20feb2019473fd679-4af3-4406-9eb9-6f95540a1c14.pdf?sfvrsn=4812bd88_1&download=true ).
Bernstein HH, Bocchini JA, Committee On Infectious D. The need to optimize adolescent immunization. Pediatrics. 2017;139(3):e20164186. https://doi.org/10.1542/peds.2016-4186 .
doi: 10.1542/peds.2016-4186
pubmed: 28167517
Gallagher KE, Kadokura E, Eckert LO, Miyake S, Mounier-Jack S, Aldea M, et al. Factors influencing completion of multi-dose vaccine schedules in adolescents: a systematic review. BMC Public Health. 2016;16(1):172. https://doi.org/10.1186/s12889-016-2845-z .
doi: 10.1186/s12889-016-2845-z
pubmed: 26895838
pmcid: 4759915
Moss JL, Reiter PL, Brewer NT. Concomitant adolescent vaccination in the US, 2007–2012. Am J Prev Med. 2016;51(5):693–705. https://doi.org/10.1016/j.amepre.2016.05.013 .
doi: 10.1016/j.amepre.2016.05.013
pubmed: 27374208
pmcid: 5067176
Alderfer J, Srivastava A, Isturiz R, Burman C, Absalon J, Beeslaar J, et al. Concomitant administration of meningococcal vaccines with other vaccines in adolescents and adults: a review of available evidence. Hum Vaccin Immunother. 2019;15(9):2205–16. https://doi.org/10.1080/21645515.2019.1581542 .
doi: 10.1080/21645515.2019.1581542
pubmed: 30779683
pmcid: 6773407